Skin Disease-Focused AnaptysBio Earns Analyst Upgrade On Positive Outlook For Clinical Triggers
Skin Disease-Focused AnaptysBio Earns Analyst Upgrade On Positive Outlook For Clinical Triggers
Monday, AnaptysBio Inc (NASDAQ:ANAB) reported a fourth-quarter 2023 EPS of $(1.59), slightly better than the consensus of $(1.60).
週一，AnaptysBio Inc（納斯達克股票代碼：ANAB）公佈的2023年第四季度每股收益爲1.59美元（1.59美元），略好於市場普遍預期的美元（1.60美元）。
The company reported sales of $9.01 million, surpassing the consensus of $2.23 million.
該公司公佈的銷售額爲901萬美元，超過了市場預期的223萬美元。
The company's year-end 2023 cash and investments of $417 million are expected to provide a cash runway through year-end 2026.
該公司2023年年底的4.17億美元現金和投資預計將在2026年底之前提供現金流。
Wedbush upgraded AnaptysBio, anticipating that a sequence of derivative developments and the company's internal clinical triggers will boost the company's stock in the next 1-1.5 years.
Wedbush對AnaptysBio進行了升級，預計一系列衍生品開發和公司的內部臨床觸發因素將在未來1-1.5年內提振該公司的股票。
Wedbush upgrades AnaptysBio from Neutral to Outperform, with a price target of $34, up from $20.
Wedbush將AnaptysBio從中性上調至跑贏大盤，目標股價從20美元上調34美元。
The company maintained guidance for Phase 2 data for its ANB032 in atopic dermatitis patients and Phase 2b data for rosnilimab in rheumatoid arthritis in mid-2025, and Phase 2 results in ulcerative colitis in the first half of 2026.
該公司維持了2025年中期特應性皮炎患者的 ANB032 的2期數據和類風溼關節炎中rosnilimab的2b期數據的指導方針，以及2026年上半年潰瘍性結腸炎的2期結果的指導方針。
Before AnaptysBio announces its results, Wedbush anticipates a significant development from its main competitor in the PD-1 agonist field, Eli Lilly And Co (NYSE:LLY). Eli Lilly's peresolimab showed enhancements in ACR20 response rates and DAS28-CRP scores compared to placebo at the highest doses.
在AnaptysBio公佈業績之前，Wedbush預計其在PD-1激動劑領域的主要競爭對手禮來公司（紐約證券交易所代碼：LLY）將取得重大進展。與最高劑量的安慰劑相比，禮來公司的peresolimab顯示，ACR20 的反應率和 DAS28-CRP 分數都有所提高。
However, there were no notable enhancements in ACR50 or ACR70 response rates, suggesting a restricted depth of response for patients individually and a potential opportunity for improvement with rosnilimab.
但是，ACR50 或 ACR70 的反應率沒有顯著提高，這表明患者的個體反應深度有限，而使用 rosnilimab 可能有改善的機會。
According to a Wedbush analyst, rosnilimab shows promising potential for top-tier effectiveness due to its targeted epitope.
根據Wedbush的一位分析師的說法，由於其靶向表位，rosnilimab顯示出具有一流療效的巨大潛力。
By attaching to a specific area near the cell membrane on PD-1, rosnilimab doesn't block other signaling molecules from interacting between T cells and antigen-presenting cells. This permits the creation of a strong immune connection and ensures efficient delivery of inhibitory signals.
通過附着在PD-1細胞膜附近的特定區域，rosnilimab不會阻斷其他信號分子在T細胞和抗原呈遞細胞之間相互作用。這允許建立強大的免疫連接，並確保抑制信號的有效傳遞。
Price Action: ANAB shares are up 10.70% at $25.86 on the last check Tuesday.
價格走勢：週二的最後一次支票中，ANAB股價上漲10.70％，至25.86美元。
Photo by louis-reed for Unsplash
louis-reed 爲 Unsplash 拍攝的照片